The text starts here.

News Release

FOR IMMEDIATE RELEASE
April 4, 2000

EISAI Reaches Settlement of the Patent Infringement Relating to Eitest PIVKA II2 and Picolumi PIVKA-II2

Eisai Co., Ltd.
Sanko Junyaku Co., Ltd.


EISAI Reaches Settlement of the Patent Infringement Relating to
Eitest PIVKA II2 and Picolumi PIVKA-II2


Tokyo (April 4, 2000) - Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) today announced that a settlement has been reached with DaIIchi Radioisotope Laboratories, Ltd. of Tokyo (President: Junzo Okuda) concerning the patent infringement relating to the products Eitest PIVKA II2 and Picolumi PIVKA-II2.


In a temporary injunction of March 31, 1999, the Tokyo District Court ordered the sales and production suspension of the DaIIchi Radioisotope Laboratories product PIVKA-II2 IRMA DaIIchi. DaIIchi Radioisotope Laboratories Ltd. honored the District Court's temporary injunction ceasing production and sales of the product and a subsequent settlement was reached.


Eitest PIVKA-II2 and Picolumi PIVKA-II22 are products used for the detection of liver cell cancer and were researched and developed by Eisai Co., Ltd. and the patent for this technology expires in March 2011. Eisai has licensed the production and sales of both products to its subsidiary, Sanko Junyaku of Tokyo (President: Ryo Watanabe).


For additional inquiries contact:


Public Relations Department Eisai Co., Ltd.
4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088
  Telephone: 03-3817-5120
  Facsimile: 03-3811-3077